nach oben

Erschienen in:

07.01.2019 | Brief Article

Feasibility of Hyperfunctioning Parathyroid Gland Localization Using [¹⁸F]fluciclovine PET/CT

verfasst von: Akinyemi A. Akintayo, O. A. Abiodun-Ojo, C. Weber, J. Sharma, C. Cohen, G. Sica, R. Halkar, M. M. Goodman, D. M. Schuster

Erschienen in: Molecular Imaging and Biology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the ability of anti-1-amino-3-anti-1-amino-3-[¹⁸F]fluorocyclobutane-1-carboxylic acid ([¹⁸F]fluciclovine) positron emission tomography/X-ray computed tomography (PET/CT) in comparison to Technetium-99m 2-methoxy isobutyl isonitrile ([^99mTc]sestamibi) single-photon emission computed tomography/CT (SPECT/CT) for the localization of hyperfunctioning parathyroid glands in patients with hyperparathyroidism.

Procedures

Four patients with hyperparathyroidism underwent 60-minutes sequential neck and thorax PET/CT after [¹⁸F]fluciclovine (352 ± 28 MBq) injection. Lesion uptake and target-to-background ratios (TBR) were compared with [^99mTc]sestamibi (798 ± 27 MBq) SPECT/CT in the same patient.

Results

Both techniques detected 4/5 hyperfunctioning parathyroid glands identified at surgery. The highest [¹⁸F]fluciclovine uptake and TBRs were at 5–9 min with rapid washout. [^99mTc]sestamibi had significantly higher TBRs compared with [¹⁸F]fluciclovine (5–9 min) for blood pool (10.9 ± 4.7 vs 1.3 ± 0.6; p < 0.01) and reference muscle backgrounds (5.8 ± 3.0 vs 1.7 ± 0.6; p < 0.01), with non-significant trend for thyroid tissue background (1.3 ± 0.5 vs 1.1 ± 0.5; p = 0.73).

Conclusion

Hyperfunctioning parathyroid glands can be detected on [¹⁸F]fluciclovine PET/CT at early imaging, but conspicuity (TBR) is better with [^99mTc]sestamibi. [¹⁸F]fluciclovine PET/CT does not seem promising in the detection of hyperfunctioning parathyroid glands.

Bilezikian JP, Bandeira L, Khan A, Cusano NE (2018) Hyperparathyroidism. Lancet 391:168–178CrossRef

Udelsman R, Lin Z, Donovan P (2011) The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg 253:585–591CrossRef

Kunstman JW, Kirsch JD, Mahajan A, Udelsman R (2013) Clinical review: parathyroid localization and implications for clinical management. J Clin Endocrinol Metab 98:902–912CrossRef

Kluijfhout WP, Pasternak JD, Beninato T, Drake FT, Gosnell JE, Shen WT, Duh QY, Allen IE, Vriens MR, de Keizer B, Hope TA, Suh I (2017) Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. Eur J Radiol 88:117–128CrossRef

Lopez Hanninen E, Vogl TJ et al (2000) Preoperative contrast-enhanced MRI of the parathyroid glands in hyperparathyroidism. Investig Radiol 35:426–430CrossRef

Gotway MB, Reddy GP, Webb WR, Morita ET, Clark OH, Higgins CB (2001) Comparison between MR imaging and ¹⁸Tc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology 218:783–790CrossRef

Stern S, Tzelnick S, Mizrachi A, Cohen M, Shpitzer T, Bachar G (2018) Accuracy of neck ultrasonography in predicting the size and location of parathyroid adenomas. Otolaryngol Head Neck Surg 159:968–972. https://doi.org/10.1177/0194599818792236 PubMedCrossRef

Mitchell BK, Merrell RC, Kinder BK (1995) Localization studies in patients with hyperparathyroidism. Surg Clin North Am 75:483–498CrossRef

Ruda JM, Hollenbeak CS, Stack BC Jr (2005) A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 132:359–372CrossRef

10.

Biertho LD, Kim C, Wu HS, Unger P, Inabnet WB (2004) Relationship between sestamibi uptake, parathyroid hormone assay, and nuclear morphology in primary hyperparathyroidism. J Am Coll Surg 199:229–233CrossRef

11.

Chien D, Jacene H (2010) Imaging of parathyroid glands. Otolaryngol Clin N Am 43:399–415CrossRef

12.

Orevi M, Freedman N, Mishani E, Bocher M, Jacobson O, Krausz Y (2014) Localization of parathyroid adenoma by ¹¹C-choline PET/CT: preliminary results. Clin Nucl Med 39:1033–1038CrossRef

13.

Parvinian A, Martin-Macintosh EL, Goenka AH, Durski JM, Mullan BP, Kemp BJ, Johnson GB (2018) ¹¹C-choline PET/CT for detection and localization of parathyroid adenomas. AJR Am J Roentgenol 210:418–422CrossRef

14.

Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, Tsybrovskyy O, Langsteger W, Pirich C (2018) ¹⁸F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with ^99mTc-MIBI or ^99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging 45:1762–1771CrossRef

15.

Quak E, Blanchard D, Houdu B, le Roux Y, Ciappuccini R, Lireux B, de Raucourt D, Grellard JM, Licaj I, Bardet S, Reznik Y, Clarisse B, Aide N (2018) F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging 45:658–666CrossRef

16.

Weber T, Gottstein M, Schwenzer S, Beer A, Luster M (2017) Is C-11 methionine PET/CT able to localise sestamibi-negative parathyroid adenomas? World J Surg 41:980–985CrossRef

17.

Oksuz MO, Dittmann H, Wicke C et al (2011) Accuracy of parathyroid imaging: a comparison of planar scintigraphy, SPECT, SPECT-CT, and C-11 methionine PET for the detection of parathyroid adenomas and glandular hyperplasia. Diagn Interv Radiol 17:297–307PubMed

18.

Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, Duh QY, Allen IE, Vriens MR, de Keizer B, Pampaloni MH, Suh I (2016) Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbeck's Arch Surg 401:925–935CrossRef

19.

Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335–339CrossRef

20.

Neumann DR, Esselstyn CB Jr, MacIntyre WJ et al (1994) Primary hyperparathyroidism: preoperative parathyroid imaging with regional body FDG PET. Radiology 192:509–512CrossRef

21.

Sisson JC, Thompson NW, Ackerman RJ, Wahl RL (1994) Use of 2-[F-18]-fluoro-2-deoxy-D-glucose PET to locate parathyroid adenomas in primary hyperparathyroidism. Radiology 192:280CrossRef

22.

Lange-Nolde A, Zajic T, Slawik M, Brink I, Reincke M, Moser E, Hoegerle S (2006) PET with ¹⁸F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism. A pilot study. Nuklearmedizin 45:193–196CrossRef

23.

Hayakawa N, Nakamoto Y, Kurihara K, Yasoda A, Kanamoto N, Miura M, Inagaki N, Togashi K (2015) A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia. Nucl Med Commun 36:53–59CrossRef

24.

Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, Giovanella L (2018) Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-018-4123-z

Titel: Feasibility of Hyperfunctioning Parathyroid Gland Localization Using [18F]fluciclovine PET/CT
verfasst von: Akinyemi A. Akintayo
O. A. Abiodun-Ojo
C. Weber
J. Sharma
C. Cohen
G. Sica
R. Halkar
M. M. Goodman
D. M. Schuster
Publikationsdatum: 07.01.2019
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 5/2019
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-018-01309-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Feasibility of Hyperfunctioning Parathyroid Gland Localization Using [¹⁸F]fluciclovine PET/CT